Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

BIZARRE: 3 - You Need To See This

Up 45% YTD, Should You Buy This Outperforming Healthcare Stock?

Boston Scientific shows impressive growth in Q3 results, garnering bullish analyst support despite clinical trial setbacks.

Barchart

Earnings Preview: What To Expect from Boston Scientific's Report

With Boston Scientific gearing up to release its third-quarter earnings later this month, analysts expect double-digit earnings growth.

Barchart

3 'Strong Buy' Stocks to Grab Now for More Gains

For investors looking to add some high-potential stocks to their portfolio, here are three top-rated opportunities to consider now.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

Is Boston Scientific Stock Outperforming the Nasdaq?

Boston Scientific has outperformed the Nasdaq Composite over the past year, and analysts remain bullish on the stock’s prospects.

Barchart

'I'm on morphine patches every day': Woman still waiting for vaginal mesh removal four years later

‘I used to walk everywhere, but now I just potter around the house. I no longer walk to the shops,’ June Dunne tells Maya Oppenheim

The Independent UK

Women harmed by vaginal mesh in England get payout

The amount of the financial settlement has not been made public, although it is expected millions have been paid out

Evening Standard

140 women win payouts for vaginal mesh complications

Women claimed the implants caused infection, bleeding, chronic pain, bladder and bowel perforations, and problems urinating

The Independent UK

Read news from The Economist, FT, and more,
with one subscription

140 women in England receive payout for vaginal mesh implant complications

Settlement from first successful group claim in England expected to total millions of pounds, but size of payments unknown

The Guardian - UK

What Are Wall Street Analysts' Target Price for Boston Scientific Stock?

Boston Scientific has outperformed the broader market over the past year, and analysts remain bullish about the stock’s prospects.

Barchart

How Boston Scientific's digital and IT boss upgraded her team from order takers to strategic thinkers

The $110 billion medical devices company now has a digital leader who sits on the executive management board of every division, every region, and every business function.

Fortune

Boston Scientific's Quarterly Earnings Preview: What You Need to Know

Boston Scientific is expected to report its second-quarter earnings results this month, and Wall Street analysts expect a single-digit profit growth.

Barchart

Is Boston Scientific Stock Outperforming the S&P 500?

Boston Scientific recently reached an all-time high, outperforming the S&P 500 Index, with Wall Street analysts remaining bullish about the stock’s prospects.

Barchart

Boston Scientific Stock: Is Wall Street Bullish or Bearish?

Boston Scientific has significantly outperformed the broader market YTD, and Wall Street analysts are still bullish about the stock’s prospects.

Barchart

3 Safe Haven Stocks to Own in an Unpredictable Market

Even though 2024 kicked off strong, recent macroeconomic uncertainties highlight the need for resilient investments. These three “safe haven” stocks are worth considering for hedging against the market downswings.

Barchart

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

Smith & Nephew (SNN) vs. Boston Scientific (BSX): Buy or Sell as These Medical Stocks Gear up for Quarterly Earnings?

The medical devices and equipment industry is primed to make significant strides toward growth this year, a surge propelled by increasing incidences of chronic diseases and the emphasis on early detection and treatment, coupled with leaps in technological development. Given this backdrop, let’s compare medical device stocks Boston Scientific (BSX)…

Barchart

Chart of the Day: Boston Scientific - Revenue Growth Potential

The Chart of the Day belongs to the healthcare company Boston Scientific (BSX) . I found the stock by using Barchart's powerful screening functions to find stocks with the highest technical buy signals, highest Weighted Alpha, superior current momentum and having a Trend Seeker buy signal then used the Flipchart...

Barchart

Chart of the Day: Boson Scientific - Revenue Growth Potential

Barchart

Markets Today: Stocks Climb on M&A Activity and Lower Bond Yields

Morning Markets March E-Mini S&P 500 futures (ES H24) are up +0.06%, and March Nasdaq 100 E-Mini futures (NQH2 4) are up +0.18%. Stock index futures this morning are moderately higher. An increase in M&A activity supports stocks after Boston Scientific agreed to buy Axionics for $3.7 billion and Johnson...

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

3 Top-Rated Growth Stocks To Buy on Every Dip

Growth stocks are down, but don't count them out. Here are three top-rated names worth scooping up when the market pulls back.

Barchart

Chart of the Day: Boston Scientific - Medical Technology

The Chart of the Day belongs to the medical technology company Boston Scientific (BSX) . I found the stock by using Barchart's powerful screening functions to find stocks with the highest technical buy signals, highest Weighted Alpha, superior current momentum and having a Trend Seeker buy signal then used the...

Tribune News Service

Texas biotech company, UT win $42 million patent case against Boston Scientific

A small Dallas biotech company and the University of Texas took on big pharma and won.

The Guardian - AU

Johnson & Johnson reaches $300m settlement over pelvic mesh implants

Settlement of two Australian class actions is largest in country’s history and subject to federal court approval

Benzinga

Coinbase Global, T-Mobile US And 2 Other Stocks Insiders Are Selling

U.S. crude oil futures traded lower this morning on Tuesday. Investors, meanwhile, focused on some notable insider trades.

Benzinga

Accenture And 3 Other Stocks Insiders Are Selling

Johnson & Johnson (NYSE: JNJ) reported upbeat earnings for its second quarter, but lowered its FY22 guidance. Investors, meanwhile, focused on some notable insider trades.

The Guardian - AU

Boston Scientific to pay $105m to Australian women who received pelvic mesh implants

Lawyer says settlement will provide compensation for women who suffered pain and complications from pelvic mesh

1 2 3 4

People

Sristi Suman JayaswalThe

216 stories

Vujcic

14 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.